NHS South East to deploy autonomous AI for skin cancer triage across 18 trusts

Skin Analytics’ DERM will go live across all 18 NHS South East trusts from autumn, making the region the largest NHS rollout of autonomous medical AI to date. The deployment is designed to speed triage, free consultant time and expand access to earlier skin cancer detection for about 9 million people.

Why it matters: - The NHS South East rollout could change how suspected skin cancer referrals are handled across a region covering about 9 million people. - Skin Analytics says the deployment is the largest rollout of autonomous medical AI in NHS history. - The system is meant to discharge benign cases earlier, speed up specialist care for higher-risk patients and reduce pressure on dermatology services. - Modelling for the three-year rollout suggests up to one-third of urgent suspected skin cancer referrals could be safely discharged before a first outpatient appointment. - The same modelling estimates 13,500 consultant hours a year could be released, equal to about 27,000 additional appointments across the region.

What happened: - Skin Analytics said DERM will go live across all 18 NHS South East trusts from autumn. - The rollout will extend autonomous skin cancer triage to the whole NHSE South East region. - DERM is already an integrated part of NHS dermatology pathways and is in use in 25 NHS trusts across NHS England. - The platform has assessed more than 250,000 patients and identified more than 25,000 cancers. - The NHSE South East move follows Northern Ireland’s decision to approve DERM for autonomous assessment of skin cancer lesions across that region.

The details: - DERM is the first and only AI certified for autonomous use under Class III CE marking. - The system is built and regulated in the UK and operates under NHS data governance, clinical safety and security standards. - Skin Analytics says DERM correctly rules out skin cancer 99.5% of the time. - The company says the tool has been independently proven to perform at least as well as a face-to-face dermatologist assessment. - Histopathology has validated the findings, and the company describes histopathology as the diagnostic gold standard. - Patients with benign lesions can be discharged at the triage stage. - Patients flagged as higher risk can be fast-tracked to a specialist. - Skin cancer cases are rising, and early detection is presented as a key factor in survival. - The rollout is intended to lower the downstream cost to the NHS of treating skin cancer at a later stage.

Between the lines: - The deployment shows the NHS is willing to use autonomous AI, not just decision-support software, inside cancer pathways. - That makes the South East rollout a test case for how far clinical automation can go while staying inside NHS governance and regulatory guardrails. - The staffing impact matters as much as the diagnostic one, because the shortage of dermatologists is already stretching referral pathways. - Dr Alexandra Kemp said AI DERM has helped her trust move harmless lesions off the cancer pathway faster, so dermatologists can focus on true skin cancers and other skin conditions. - Daghni Rajasingam said the rollout could help patients get reassurance sooner and free up clinical time for more complex cases. - Neil Daly called the NHS partnership a “real world first” because he says it brings autonomous AI into cancer pathways at this scale.

What’s next: - DERM is expected to continue expanding its role in NHS dermatology pathways as the South East rollout begins from autumn. - The three-year deployment will be watched for whether the projected discharge rates, time savings and appointment gains materialize in practice. - If the rollout performs as modeled, it could become a template for wider use of autonomous medical AI across the NHS.

The bottom line: - The NHS South East is about to become the biggest real-world test yet of autonomous AI in cancer triage, with speed, capacity and earlier detection all on the line.